BioStress Lab secures £300k in angel investment and grant funding to develop its stress management software.
The Wakefield-based company raised capital from angel investors and Innovate UK to advance its biometric platform.
Share allotment filed at Companies House
BioStress Lab provides a biometric platform designed to measure workplace stress, track employee wellbeing, and reduce costs related to absenteeism.
BioStress Lab has secured £300k in funding to support the development of its biometric workplace stress management software.
The capital comprises £150k in angel investment sourced via the NorthInvest and Newcastle Angel Hub networks, alongside a £150k grant from Innovate UK through the Regional Angel Investment Accelerator programme.
The Wakefield-based company, founded in 2020, uses biometric data to measure workplace stress and improve employee wellbeing through its BIO programme. The proceeds will be directed towards software development to enable rapid scaling of the business.
From the founder
"We are excited to be taking this big step to revolutionise workplace stress management and tackle the debilitating economic and health effects of stress. We would like to thank our investors, Innovate UK and NorthInvest – this funding will help further develop our technology and accelerate our global growth."
Tim Wade
CEO at BioStress Lab
Investor perspective
"Having worked closely with BioStress Lab on refining their pitch and proposition during one of our investor-readiness programmes, it’s extremely rewarding to see them receive such a big investment."
Jordan Dargue
Board Director, NorthInvest
Use of funds
- 01Continue product development
Investors
Categories
About the company
BioStress Lab
BioStress Lab develops biometric software to measure and manage workplace stress.